{
    "clinical_study": {
        "@rank": "72071", 
        "arm_group": [
            {
                "arm_group_label": "ABT-436", 
                "arm_group_type": "Experimental", 
                "description": "Subject receiving ABT-436"
            }, 
            {
                "arm_group_label": "Escitalopram", 
                "arm_group_type": "Active Comparator", 
                "description": "Subject receiving escitalopram."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subject receiving placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder."
        }, 
        "brief_title": "Efficacy and Safety Study of ABT-436 in Major Depressive Disorder", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a primary Diagnostic and Statistical Manual of Mental Disorders-Fourth\n             Edition-Text Revision diagnosis of major depressive disorder without psychotic\n             features\n\n          -  No current antidepressant treatment within 7 half-lives or 2 weeks, whichever is\n             longer, prior to Day minus 1.\n\n          -  Can safely be treated on an outpatient basis.\n\n          -  A condition of general good physical health.\n\n          -  Surgically sterile, using a highly effective method of birth control or (if female)\n             at least 1 year post menopausal.\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity, intolerance or adverse reaction to escitalopram that led\n             to discontinuation, or hypersensitivity to citalopram.  History of serotonin\n             syndrome.\n\n          -  Inadequate response to more than two different antidepressant medications during the\n             current major depressive episode.\n\n          -  History of electroconvulsive therapy, vagal nerve stimulation or deep brain\n             stimulation.\n\n          -  History of transcranial magnetic stimulation during the current major depressive\n             episode.\n\n          -  Psychotherapy that has not been ongoing for at least 3 months prior to Day minus 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741142", 
            "org_study_id": "M11-733"
        }, 
        "intervention": [
            {
                "arm_group_label": "ABT-436", 
                "description": "Subjects receiving ABT-436", 
                "intervention_name": "ABT-436", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Escitalopram", 
                "description": "Subjects receiving escitalopram", 
                "intervention_name": "Escitalopram", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subject receiving placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Major Depressive Disorder", 
        "lastchanged_date": "October 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72211"
                    }, 
                    "name": "Site Reference ID/Investigator# 85593"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }, 
                    "name": "Site Reference ID/Investigator# 87228"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "National City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91950"
                    }, 
                    "name": "Site Reference ID/Investigator# 87214"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94612"
                    }, 
                    "name": "Site Reference ID/Investigator# 87220"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34201"
                    }, 
                    "name": "Site Reference ID/Investigator# 87215"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Site Reference ID/Investigator# 87225"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30328"
                    }, 
                    "name": "Site Reference ID/Investigator# 85594"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "Site Reference ID/Investigator# 85580"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11235"
                    }, 
                    "name": "Site Reference ID/Investigator# 87227"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10128"
                    }, 
                    "name": "Site Reference ID/Investigator# 87223"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45417"
                    }, 
                    "name": "Site Reference ID/Investigator# 87217"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Site Reference ID/Investigator# 87226"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "Site Reference ID/Investigator# 87221"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Site Reference ID/Investigator# 87219"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Site Reference ID/Investigator# 87216"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77008"
                    }, 
                    "name": "Site Reference ID/Investigator# 87933"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "Site Reference ID/Investigator# 88874"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Site Reference ID/Investigator# 88876"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Beatrice Rendenbach-Mueller, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.", 
            "measure": "Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.", 
            "measure": "Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013", 
        "why_stopped": "Decision based on strategic determination; not safety."
    }
}